GALLIXA

Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, and pharmaceuticals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations namely,appetite suppressants; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics for human use; Pharmaceuticals, namely, lipid lowering agents; all of the foregoing shall be exclusively for human use